Figure 2
SB1518 effectively blocks signaling pathways in JAK2V617F-expressing cell lines. (a) SET-2 and (b) HEL92.1.7 cells were treated for 3 h with SB1518. After lysis, pJAK2 (Y1007/8) was detected by immunoblotting (IB) with anti-p(1007/8)JAK2 antibody, followed by re-probing of the same membrane with anti-JAK2, anti-pSTAT3(Y705), anti-pSTAT5(Y694) and anti-actin antibody. (c) HEL92.1.7 cells were treated for 3 h with three JAK2 inhibitors (1, TG101348; 2, INCB018424; 3, JAK inhibitor-1) as indicated and pJAK2 (Y1007/8) and total JAK2 were detected by immunoblotting. (d) HEL92.1.7 cells were treated with 1 μM SB1518 for the indicated times and pJAK2 (Y1007/8) and JAK2 were detected by IB. (e) HEL92.1.7 cells were treated with 1 μM SB1518 for 3 h and pJAK2 (Y1007/8), pJAK2 (Y221) and JAK2 were detected by IB.
